Remicade 2021 U.S. PROMOTIONAL AUDIT REPORT

Published July 2022 • 28 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Remicade through reportable promotional activity in 2021 and how does this compare to its peer set in the Ankylosing Spondylitis, Crohn’s Disease, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does J&J’s depth of coverage vary within key specialties (e.g., Dermatology, Physician Assistant, Nursing, Rheumatology, and Gastroenterology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Remicade throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Remicade in 2021?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 40,510 paid interactions across 10,920 physicians made on behalf of Remicade were carefully examined to support our analysis. In addition, interaction data from 32 peer products (e.g. Actemra, Avsola, Cimzia, Cosentyx, Duobrii, Enbrel, Enstilar, Entyvio, Humira, Ilaris, Ilumya, Inflectra, Kevzara, Kineret, Naprelan, Olumiant, Orencia, Otezla, Rayos, Renflexis, Rinvoq, Rituxan, Siliq, Simponi, Skyrizi, Stelara, Taltz, Tremfya, Uceris, Ultravate, Xeljanz, and Zeposia ) was leveraged to provide benchmarking and market insights.